Explore high-purity API standards, peptide reagents, and solid-phase synthesis batches engineered for clinical and industrial formulation development.
A 28-amino-acid synthetic acid-stable peptide critical for systemic immunomodulation and pharmaceutical formulation.
Thymosin Alpha 1 (commonly designated as Ta1 Peptide or Tα1, CAS Registry Number: 62304-98-7) is an acetylated polypeptide hormone originally isolated from bovine thymic tissue extract (Thymosin Fraction 5). The primary sequence is strictly defined as:
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.
Due to its complete lack of internal disulfide crosslinks and an isoelectric point (pI) centered at approximately 4.12, Ta1 features an acidic, highly hydrophilic profile requiring stringent solid-phase peptide synthesis (SPPS) controls to suppress racemization, beta-sheet aggregation, and aspartimide rearrangements during prolonged cycle additions.
| Analytical Parameter | Commercial Research Grade | Clinical Trial & Formulation Grade | Commercial cGMP Pharmaceutical API |
|---|---|---|---|
| HPLC Chromatographic Purity | ≥ 95.0% (Area%) | ≥ 98.0% (Area%) | ≥ 99.0% - 99.5% (Max Single Impurity ≤ 0.5%) |
| Identity Confirmation | ESI-MS / MALDI-TOF (±1 Da) | High-Res MS (HRMS) & Amino Acid Analysis | HRMS, AAA, LC-MS/MS Sequencing, 1H/13C NMR |
| Counter-Ion Distribution | Trifluoroacetate (TFA) residual | Acetate (≤ 12.0% w/w) | Acetate (Controlled 6.0% - 10.0%, TFA ≤ 0.1%) |
| Peptide Net Content | ≥ 75.0% | ≥ 80.0% | ≥ 85.0% to 90.0% (by quantitative HPLC/Nitrogen) |
| Bacterial Endotoxin | N/A or ≤ 10 EU/mg | ≤ 2.0 EU/mg | ≤ 0.05 EU/mg (Strict Sterile Injectable Standard) |
| Residual Solvents (ICH Q3C) | Unmonitored | DMF, Piperidine, DCM ≤ 1000 ppm | Class 1 None; Class 2/3 below ICH Q3C safety limits |
Wholesale procurement directors frequently encounter price disparities when reviewing vendor quotes. A quote offering Ta1 at lower nominal costs often reflects gross weight inclusive of 15%–25% counter-ion salts (trifluoroacetate or acetate adducts) and hygroscopic moisture. High-grade API procurement from Hangzhou Thinheal Pharma-Tech guarantees standardized net peptide content calculation, ensuring true biological titer and formulation dosing precision.
A transparent breakdown of cost structures, volumetric economies of scale, and batch manufacturing dynamics for global sourcing directors.
Ideal for pre-clinical evaluation, pharmacodynamic screening, and formulation stability trials. Produced via automated microwave-assisted or continuous-flow SPPS with rapid 2–3 week delivery. Pricing generally scales around $120 – $280 per gram depending on lyophilized salt exchange and required chromatographic documentation.
Engineered for IND filings, animal toxicology GLP batches, and pilot pharmaceutical filling. Features comprehensive ICH Q2 analytical validation, impurity profiling, and low-bioburden lyophilization. Pricing benefits from raw protected amino acid bulk efficiencies, stabilizing at competitive multi-hundred gram contracts.
Dedicated reactor campaigns running in 500L–2000L solid-phase reaction vessels. Features full Drug Master File (DMF) support, automated counter-current chromatography purification, and multi-year supply chain agreements with locked-in floor pricing for global pharmaceutical brand owners.
The production economics of Ta1 differ markedly from short oligopeptides. Because it contains 28 residues including multiple glutamic acid (Glu), aspartic acid (Asp), and lysine (Lys) moieties, the synthesis demands substantial molar excesses of high-purity Fmoc-protected building blocks, expensive coupling reagents (e.g., Oxyma/DIC or HATU), and extensive preparative reverse-phase HPLC passes to eliminate n-1 deletion fragments and diastereomers. Hangzhou Thinheal Pharma-Tech’s multi-ton automated footprint eliminates manual synthesis bottlenecks, driving downstream COGS down by 25%–38% compared to European or US regional manufacturers.
How Thymosin Alpha 1 serves as an anchor molecule across global oncology, infectious disease control, and immune engineering.
Ta1 is clinically documented to stimulate T-cell precursor maturation into functional CD4+/CD8+ subsets, counteracting the profound myelosuppression and lymphopenia induced by platinum- and taxane-based chemotherapies. In synergistic immunooncology regimens, Ta1 upregulates major histocompatibility complex (MHC) Class I expression, expanding tumor antigen presentation for programmed death receptor-1 (PD-1/PD-L1) checkpoint inhibitor responsiveness.
During severe sepsis and septic shock, intensive care units encounter secondary mortality triggered by immune paralysis. Ta1 administration downregulates lymphocyte apoptosis, promotes anti-inflammatory balance, and reduces 28-day mortality in multi-center clinical trials, establishing itself as a lifesaving hospital API.
By potentiating natural killer (NK) cell cytotoxicity and elevating endogenous interferon-gamma (IFN-γ) and interleukin-2 (IL-2) secretion, Ta1 aids in achieving sustained virological response and HBeAg seroconversion in chronic hepatitis B patients who exhibit intolerance or resistance to nucleoside analogues.
In elderly and immunocompromised cohorts exhibiting blunted antibody titers post-vaccination (influenza, hepatitis, emerging coronavirus spikes), co-administration of synthetic Ta1 significantly improves seroconversion rates and cellular memory retention without exacerbating systemic reactogenicity.
During global viral respiratory outbreaks, Tα1 proved vital in tempering cytokine storms while sustaining absolute lymphocyte counts. National biodefense stockpiles maintain strategic reserves of lyophilized Ta1 API for rapid reconstitution against pandemic pathogens.
Navigating pharmaceutical registration, quality auditing, and export compliance across major international jurisdictions.
In China and Southeast Asia, Thymosin Alpha 1 is widely recognized under brand names such as Zadaxin and numerous domestic generic injections. Thinheal provides complete Type II Active Substance Dossiers registered under the National Medical Products Administration (NMPA) CDE platform, simplifying mutual regulatory approvals in South Korea, Vietnam, and the ASEAN region.
While marketed globally, Ta1 holds Orphan Drug Designations in the United States for conditions such as hepatocellular carcinoma and cystic fibrosis. Thinheal supports US partners with Type II Drug Master Files (DMF) maintained in eCTD format, backed by Letters of Authorization (LoA) for generic ANDA and investigational IND development.
European Union member states require rigorous CEP (Certificate of Suitability) documentation or active substance master files (ASMF). Our dedicated CIS desk manages full dossier compliance tailored to the Eurasian Economic Union pharmacopeia, featuring dual-language Certificates of Analysis in Russian and English.
Transitioning from traditional batch peptide synthesis toward continuous-flow green chemistry and automated process analytical technology (PAT).
Utilizing 2-chlorotrityl chloride resin (2-CTC) to suppress C-terminal racemization of Asn28. N,N-diisopropylethylamine (DIPEA) catalyzed couplings monitored by automated UV sensors.
Micro-reactor flow synthesis lowering coupling times from 45 minutes to 3.5 minutes per residue, eliminating thermal hotspots and reducing solvent consumption by 42%.
Replacing DMF and NMP with eco-friendly alternatives (Cyrene, 2-MeTHF) to fulfill strict EU REACH guidelines while enhancing purity profiles through higher resin swelling.
Deep learning models predicting secondary structure folding anomalies during chain elongation, ensuring near 100% crude purity and lowering preparative HPLC cycles.
Ensure regulatory compliance and batch reproducibility with these essential vendor auditing checkpoints.
Insist on gradient RP-HPLC capable of resolving D-Asp and D-Ser diastereomers. Truncated (n-1, n-2) deletion peptides must be comprehensively mapped via high-resolution LC-MS/MS with documented retention windows.
Standard synthetic cleavage yields TFA salts cytotoxic in high concentrations. Ensure your supplier implements validated ion-exchange chromatography converting TFA to pharmaceutical acetate salts (≤ 0.1% TFA threshold).
Ta1 is primarily formulated for subcutaneous or intramuscular parenteral delivery. The lyophilized bulk API must be processed in Class A/B cleanroom zones with continuous particle monitoring and endotoxin limits <0.05 EU/mg.
Practical answers to commercial inquiries routinely addressed by Thinheal's technical sales engineers.
Discover additional high-barrier peptide drug substances, incretin analogues, and tissue repair peptides manufactured at our multi-ton synthesis base.
Hangzhou Thinheal Pharma-Tech Co., Ltd. combines nearly 20 years of core management expertise, multi-ton solid-phase peptide synthesis facilities, and four dedicated international desks to deliver premier quality, price leadership, and regulatory security for every batch.
Thin
